Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Garden of Life buy grows Atrium sales

This article was originally published in The Tan Sheet

Executive Summary

The acquisition of Garden of Life contributes to a 27.6 percent jump in Atrium Innovations' first-quarter revenue to $90.1 million. The Quebec City-based health product company purchased Garden of Life in September 2009 to bolster U.S. distribution, and it seeks a greater share of the Canadian supplement market with its April acquisition of Trophic Canada (1"The Tan Sheet" April 12, 2010, In Brief). Atrium May 11 reported net earnings rose 22.8 percent to $13 million in the January-March period - or 39 cents in diluted net earnings per share, up 21.9 percent. Sales in Germany were lower than expected, due to slow consumer acceptance of the new Wobenzym P anti-inflammatory formula, a brand acquired from German company Mucos Emulsions in 2007. CEO Pierre Fitzgibbon said Atrium is working through the challenges posed by Wobenzym P, which sells through doctors and pharmacists

You may also be interested in...

Atrium Innovations acquires Trophic Canada

Atrium Innovations' $11 million acquisition of the vitamin, mineral and supplement maker and distributor Trophic Canada gives the marketer "a stronger and complementary foothold" in the Canadian market. Trophic's two brands, Trophic and Wild Rose, include 150 products and sell approximately $7.5 million annually, primarily in specialized health food stores, according to Atrium's March 18 release. Atrium entered health food stores last September with the acquisition of Garden of Life (1"The Tan Sheet" Sept. 22, 2009). Before that it acquired enzyme manufacturer Enyzm-Arzeimittel-Berlin (2"The Tan Sheet" May 25, 2009, In Brief)

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.

Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales

Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts